Herbalife Nutrition Ltd vs DENTSPLY SIRONA Inc — how do they compare? Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: DENTSPLY SIRONA Inc is the larger of the two by market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| HLF | XRAY | |
|---|---|---|
Market Cap | $1.34B | $1.73B |
Volume | 1,589,457 | 6,198,582 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $14.68 |
52-Week Low | $7.75 | $8.52 |
Typical Hold Time | 43 Days | 72 Days |
Enterprise Value | $3.18B | $3.80B |
Dividend Yield | — | 5.04% |
Signals from Pluang's Aura AI — not financial advice
Herbalife (HLF) trades at $13.03, up 3.0% with a bullish technical signal. The stock shows attractive valuation metrics with P/E of 8.22 and P/S of 0.26, while maintaining strong gross margins of 77.7%. Recent Q1 2026 earnings beat expectations, though Q2 2026 missed. The company announced a $250 million share repurchase program and CEO transition, with management reaffirming 2026 guidance. Cash flow trends show improvement with projected positive net cash flow of $50 million for 2026.
HLF presents a value opportunity with discounted valuation and improving debt profile, though execution risks remain. Analyst consensus targets $19.00 (53.8% upside) with 14 buy ratings. Key risks include mixed earnings performance, high debt levels despite recent reduction, and leadership transition. The stock offers potential for re-rating if management delivers on margin expansion and growth targets outlined in recent investor presentations.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →